文献速递消化系统肿瘤

仅肺转移性胰腺癌:患者特征、分子谱与生存差异

Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival.
PubMed 文献 · Eur J Cancer · 2026-01-09

该回顾性研究纳入2010至2022年单中心1012例转移性胰腺导管腺癌(PDAC)患者,比较不同转移部位患者的特征与生存。仅肺转移占11%,该类患者更多为女性、转移诊断时年龄更大、同时性转移更少,液体活检KRAS与TP53突变检出更低,中位OS达28.7个月,显著优于其他部位转移者。

要点

  • 仅肺转移PDAC患者中位OS为28.7个月,显著优于肝、腹膜及其他部位转移。
  • 仅肺转移患者更多为女性、转移诊断年龄更大、同时性转移比例更低。
  • 仅肺转移患者液体活检KRAS与TP53突变检出更低,局部治疗可能改善预后。

核心结论

  • 仅肺转移PDAC患者总生存优于其他转移部位患者,更多为女性且KRAS突变检出更少。
  • 该类患者可能代表具有特定生物学特征与较好预后的PDAC亚群,局部治疗可能进一步改善预后。

研究设计与样本

  • 单中心回顾性分析,纳入2010至2022年所有转移性PDAC患者共1012例。
  • 仅肺转移定义为转移诊断时仅有肺转移。

主要发现

  • 1012例中仅肺转移109例(11%),仅肝转移506例(50%),仅腹膜转移94例(9%),其他或多部位转移303例(30%)。
  • 仅肺转移组女性占63%对比其他组46%,转移诊断中位年龄66岁对比63岁(p=0.01),同时性转移占42%对比69%(p<0.001)。
  • 仅肺转移组液体活检KRAS与TP53突变检出更低,但肿瘤组织检测未见差异。
  • 中位OS:仅肺转移28.7个月(95%CI 23.3-38.6),仅肝转移13.5个月(95%CI 12.4-14.6),仅腹膜转移11.5个月(95%CI 9.6-16.9),其他患者11.3个月(95%CI 10.0-13.8),p<0.0001。
  • 仅肺转移患者中接受局部治疗者(n=15)预后更好。

临床怎么用

  • 对仅肺转移PDAC患者应认识到其相对较好预后,治疗决策与咨询时可参考此差异。
  • 仅肺转移患者可考虑局部治疗以进一步改善预后。
  • 液体活检分子检测结果在仅肺转移患者中可能低估KRAS与TP53突变,必要时结合组织检测。

局限性

  • 单中心回顾性研究设计。
  • 仅肺转移患者中接受局部治疗者样本量小(n=15)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A better prognosis is suggested for lung-only metastases patients with pancreatic ductal adenocarcinoma (PDAC), yet biological/clinical underpinnings of organotropism in PDAC remain unclear. Study objective was to compare PDAC patients depending on their metastatic site with a special focus on "lung-only" metastases patients. METHODS: A retrospective analysis included all patients with metastatic PDAC between 2010 and 2022 in an academic-center. Lung-only patients were defined as patients with only lung metastases at diagnosis of metastases. RESULTS: Among 1012 patients, 109 (11 %) presented lung-only metastases, 506 patients (50 %) liver-only, 94 (9 %) peritoneal-only and 303 (30 %) other or multiple sites. Compared with others, lung-only patients were more frequently female (63 % vs. 46 %), older at metastatic diagnosis (median 66 vs. 63 years, p = 0.01), and less likely to have synchronous metastases (42 % vs. 69 %, p < 0.001). ctDNA detection was lower in the lung-only group with less KRAS mutations and TP53 mutations detected with liquid biopsy (but no difference was observed using tumor tissue). Median OS was higher in the lung-only group with 28.7 months (95 %CI [23.3-38.6]) vs 13.5 months (95 %CI [12.4-14.6]) for liver-only group, 11.5 months (95 %CI [9.6-16.9]) for peritoneal-only group and 11.3 months (95 %CI [10.0-13.8]) for other patients (p < 0.0001). Among lung-only patients, local treatments (n = 15) had a positive prognostic impact. CONCLUSIONS: Patients with lung-only metastases had a better OS than others, were more often women, and harbored less KRAS mutations. Our results argue in favor of PDAC with specific characteristics, especially a better prognosis, possibly further enhanced by the possibility to perform local treatments, and less detection of ctDNA.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boilève A, Mercier L, Bonnet B, et al. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Eur J Cancer. 2026. PMID: 41547177. doi:10.1016/j.ejca.2026.116227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。